Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALP and PSA flare prognosis in mCRPC treated with docetaxel, cabazitaxel, abiraterone, or enzalutamide
NL-OMON22381Not yet recruiting
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of docetaxel, cabazitaxel, abiraterone and enzalutamide in prostate cancer (PCa), sponsored by None. Primary endpoint: Overall survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
docetaxelcabazitaxelabirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON22381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22381.